Patents by Inventor David Nalin

David Nalin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Digital stethoscope
    Patent number: 11882402
    Abstract: A digital stethoscope includes a stethoscope housing defining a housing edge. The digital stethoscope also includes a surface region secured to the stethoscope housing at the housing edge, and a number of microphones. The digital stethoscope also includes a processing device disposed within the stethoscope housing and in communication with the microphones. The processing device receives the digital audio data from the microphones.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: January 23, 2024
    Assignee: ALIVECOR, INC.
    Inventors: David Nalin Kumar, Vinod Khosla
  • DIGITAL STETHOSCOPE
    Publication number: 20230010141
    Abstract: A digital stethoscope includes a stethoscope housing defining a housing edge. The digital stethoscope also includes a surface region secured to the stethoscope housing at the housing edge, and a number of microphones. The digital stethoscope also includes a processing device disposed within the stethoscope housing and in communication with the microphones. The processing device receives the digital audio data from the microphones.
    Type: Application
    Filed: July 8, 2021
    Publication date: January 12, 2023
    Inventors: David Nalin Kumar, Vinod Khosla
  • Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
    Patent number: 11422127
    Abstract: Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 23, 2022
    Assignee: ALBANY MEDICAL COLLEGE
    Inventors: Edmund J. Gosselin, Sudeep Kumar, David Nalin
  • EX VIVO ANTIGEN AND ADJUVANT PULSED PERIPHERAL BLOOD MONONUCLEAR CELLS AS A SCREENING PLATFORM FOR CANDIDATE NOVEL VACCINES AND CANDIDATE ANTIGENS
    Publication number: 20190376951
    Abstract: Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.
    Type: Application
    Filed: December 7, 2017
    Publication date: December 12, 2019
    Applicant: ALBANY MEDICAL COLLEGE
    Inventors: Edmund J. Gosselin, Sudeep Kumar, David Nalin